Evidence map›Paper›PMID 41548163›Full record

ArticleAMB Express2026

Limosilactobacillus reuteri fermentation enhances the anti-type 2 diabetic activity of Gastrodia elata polysaccharides.

Jiajia Liu, Zongyang Li, Shixiao Pu, Xing Huang, Zixian Xu, Xiaoqi Yang, Yunlong Zhang, Chengying Luo, Shibo Li, Jiayun Miao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiajia LiuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Zongyang LiFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Shixiao PuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Xing HuangFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Zixian XuFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Xiaoqi YangFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Yunlong ZhangFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.
Chengying LuoGastrodia elata Industrial Development Center of Yiliang County, Zhaotong, 657600, Yunnan, China.
Shibo LiYunnan Senhao Fungi Industry Co., Ltd, Zhaotong, Yunnan, China.
Jiayun MiaoYunnan Senhao Fungi Industry Co., Ltd, Zhaotong, Yunnan, China.
Yicen LinFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China. yicenlin@kust.edu.cn.
Lianbing LinFaculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China. linlb@kust.edu.cn.

Funding

Major Science and Technology Plan Special Project in Yunnan Province, China CB22144SO29A
6 · The paper itself

Abstract

The development of effective and low-toxicity treatments for type 2 diabetes mellitus (T2DM) remains a critical objective in current research. Lactic acid bacteria (LAB) fermentation can biotransform plant polysaccharides and may enhance their bioactivity. Here, we investigated the fermentation with Limosilactobacillus reuteri DSM17938 fermentation affects the structure of Gastrodia elata polysaccharides and their potentail benefits in T2DM. Polysaccharides were extracted from non-fermented G. elata (GP) and from G. elata fermented with L. reuteri DSM 17,938 under controlled conditions to yield fermented polysaccharides (LGP). Fermentation reduced molecular weight and shifted monosaccharide composition, including increased content of galactose, arabinose, glucose, xylose, and galacturonic acid while decreased content of fructose. Fermentation reduced the molecular weight, altered the morphology, and shifted the monosaccharide composition, including increased content of arabinose and galacturonic acid while decreasing fructose. In a T2DM mouse model, LGP (10.9 ± 0.8 mmol/L) demonstrated a more significant hypoglycemic effect compared to GP (14.6 ± 1.4 mmol/L, p < 0.001). Furthermore, LGP more effectively improved antioxidant and inflammatory profiles markers (p < 0.001), and attenuated intestine and kidney injury. Mechanistic investigations revealed that LGP modulates gut microbiota composition by reducing the Firmicutes/Bacteroidetes ratio and promoting the proliferation of beneficial bacteria such as Kineothrix and Akkermansia, while concurrently increasing short-chain fatty acid levels and regulating serum metabolic pathways related to carbohydrate and protein digestion and absorption. This study demonstrates that LAB fermentation is an effective bioprocessing strategy for enhancing the hypoglycemic activity of GPs, offering novel insights for the production of functional foods.

Indexed as

FermentationGastrodia elata polysaccharidesGut microbiotaLimosilactobacillus reuteriType 2 diabetes mellitus

Identifiers

PMID41548163
PMCPMC12894524

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.